Xeris Biopharma Holdings, Inc. (XERS)

NASDAQ: XERS · Real-Time Price · USD
5.16
+0.68 (15.18%)
May 8, 2025, 4:00 PM EDT - Market closed
15.18%
Market Cap 806.94M
Revenue (ttm) 222.55M
Net Income (ttm) -45.08M
Shares Out 156.38M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,209,545
Open 4.48
Previous Close 4.48
Day's Range 4.44 - 5.27
52-Week Range 1.72 - 6.07
Beta 0.91
Analysts Strong Buy
Price Target 6.10 (+18.22%)
Earnings Date May 8, 2025

About XERS

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adul... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2018
Employees 394
Stock Exchange NASDAQ
Ticker Symbol XERS
Full Company Profile

Financial Performance

In 2024, Xeris Biopharma Holdings's revenue was $203.07 million, an increase of 23.89% compared to the previous year's $163.91 million. Losses were -$54.84 million, -11.92% less than in 2023.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for XERS stock is "Strong Buy." The 12-month stock price forecast is $6.1, which is an increase of 18.22% from the latest price.

Price Target
$6.1
(18.22% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pie...

11 hours ago - Seeking Alpha

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...

19 hours ago - Business Wire

Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings

Xeris Biopharma Holdings, Inc. has shown consistent double-digit growth and is expected to continue this trend, with Q1 earnings projected to drive the share price higher. Key metrics to watch include...

1 day ago - Seeking Alpha

Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025.

7 days ago - Business Wire

Xeris Announces Changes to Its Board of Directors

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative p...

5 weeks ago - Business Wire

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ...

7 weeks ago - Business Wire

Xeris Biopharma Holdings, Inc. (XERS) Q4 2024 Earnings Call Transcript

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve ...

2 months ago - Seeking Alpha

Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing...

2 months ago - Business Wire

Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

2 months ago - Business Wire

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ...

2 months ago - Business Wire

Xeris to Participate in Upcoming Investor Conferences

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

3 months ago - Business Wire

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation CHICAGO and ARLINGTON,...

3 months ago - PRNewsWire

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced it expects to generate total 2024 revenue of $203 million, which will exceed previously announce...

4 months ago - Business Wire

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ...

4 months ago - Business Wire

Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

5 months ago - Business Wire

Xeris Biopharma Holdings, Inc. (XERS) Q3 2024 Earnings Call Transcript

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants John Shannon - Chief Executive Officer Steve Pieper - Chief Financial Of...

6 months ago - Seeking Alpha

Xeris Biopharma Reports Third Quarter 2024 Financial Results

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing...

6 months ago - Business Wire

Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

6 months ago - Business Wire

Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive

Xeris Biopharma Holdings, Inc. is an overlooked specialty pharmaceutical company with three FDA-approved products, utilizing its proprietary XeriSol and XeriJect technologies to develop innovative inj...

6 months ago - Seeking Alpha

Undercovered Dozen: KinderCare Learning, Xeris Biopharma, Generac, Philips +

The 'Undercovered' Dozen highlights 12 lesser-covered stocks from October 4th - 10th, aiming to inspire discussion and provide investment ideas. WW International's pivot to GLP-1 medications raises co...

Other symbols: GNRCKLCPHG
7 months ago - Seeking Alpha

Xeris Biopharma: Time For A Reassessment

Xeris Biopharma is trading above my Buy Threshold of $2.76 and is nearing a potential breakout above the $3.25 resistance level. The company shows strong revenue growth, driven by products like Gvoke ...

7 months ago - Seeking Alpha

Xeris Biopharma Holdings, Inc. (XERS) Q2 2024 Earnings Call Transcript

Start Time: 08:30 January 1, 0000 9:03 AM ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2024 Earnings Conference Call August 08, 2024, 08:30 AM ET Company Participants John Shannon - CEO Steven ...

9 months ago - Seeking Alpha

Xeris Biopharma Reports Second Quarter 2024 Financial Results

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing...

9 months ago - Business Wire

Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

10 months ago - Business Wire

Xeris Biopharma Announces CEO Succession Plan

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ...

10 months ago - Business Wire